Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rajni Sethi, Nicholas Sanfilippo
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	prostate cancer leuprorelin hormonal deprivation therapy Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/72f39d373bb845b7bb19979e8e7aae54
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72f39d373bb845b7bb19979e8e7aae54
record_format	dspace
spelling	oai:doaj.org-article:72f39d373bb845b7bb19979e8e7aae542021-12-02T02:17:43ZSix-month depot formulation of leuprorelin acetate in the treatment of prostate cancer1178-1998https://doaj.org/article/72f39d373bb845b7bb19979e8e7aae542009-06-01T00:00:00Zhttps://www.dovepress.com/six-month-depot-formulation-of-leuprorelin-acetate-in-the-treatment-of-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.Keywords: prostate cancer, leuprorelin, hormonal deprivation therapyRajni SethiNicholas SanfilippoDove Medical Pressarticleprostate cancerleuprorelinhormonal deprivation therapyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 259-267 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer leuprorelin hormonal deprivation therapy Geriatrics RC952-954.6
spellingShingle	prostate cancer leuprorelin hormonal deprivation therapy Geriatrics RC952-954.6 Rajni Sethi Nicholas Sanfilippo Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
description	Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.Keywords: prostate cancer, leuprorelin, hormonal deprivation therapy
format	article
author	Rajni Sethi Nicholas Sanfilippo
author_facet	Rajni Sethi Nicholas Sanfilippo
author_sort	Rajni Sethi
title	Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
title_short	Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
title_full	Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
title_fullStr	Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
title_full_unstemmed	Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
title_sort	six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/72f39d373bb845b7bb19979e8e7aae54
work_keys_str_mv	AT rajnisethi sixmonthdepotformulationofleuprorelinacetateinthetreatmentofprostatecancer AT nicholassanfilippo sixmonthdepotformulationofleuprorelinacetateinthetreatmentofprostatecancer
_version_	1718402603131338752

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Ejemplares similares